Assisted Reproductive Technology Global Market Report 2024

Assisted reproductive technology (ART) involves surgically removing eggs from women's ovaries, combining them with men's sperm in a laboratory to form embryos, and then reintroducing these embryos into the woman's body. ART procedures may utilize donor eggs, donor sperm, or previously stored frozen embryos, and they are employed in the treatment of infertility related to eggs or embryos.

The primary types of assisted reproductive technology include in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and other related procedures. In-vitro fertilization (IVF) is a complex process wherein eggs are retrieved, fertilized with sperm in a laboratory to create embryos, and then implanted into the reproductive organs of women. Procedure types within ART encompass fresh non-donor, fresh donor, frozen donor, frozen non-donor, as well as embryo or egg banking. These technologies find application in various healthcare settings, including hospitals, fertility clinics, and other related facilities.

The assisted reproductive technology (ART) market research report is one of a series of new reports that provides assisted reproductive technology (ART) market statistics, including assisted reproductive technology (ART) industry global market size, regional shares, competitors with a assisted reproductive technology (ART) market share, detailed assisted reproductive technology (ART) market segments, market trends and opportunities, and any further data you may need to thrive in the assisted reproductive technology (ART) industry. This assisted reproductive technology (ART) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The assisted reproductive technology market size has grown rapidly in recent years. It will grow from $38.04 billion in 2023 to $45.42 billion in 2024 at a compound annual growth rate (CAGR) of 19.4%. The increase in the historic period can be attributed to factors such as the rise in infertility rates, evolving societal norms, increased awareness, legislative support, and an aging population.

The assisted reproductive technology market size is expected to see rapid growth in the next few years. It will grow to $91.8 billion in 2028 at a compound annual growth rate (CAGR) of 19.2%. The anticipated growth in the forecast period can be attributed to factors such as increasing maternal age, a rising demand for same-sex parenting, the prevalence of medical tourism, the expansion of healthcare infrastructure, and ongoing research and development in the field. Key trends expected in this period involve the utilization of artificial intelligence (AI), the adoption of egg freezing, the implementation of single-embryo transfer (SET), as well as the use of preimplantation genetic testing for aneuploidy (PGT-A) and genetic screening. Additionally, innovative fertility preservation techniques are expected to play a significant role in shaping the landscape of assisted reproductive technology.

The assisted reproductive technology market is anticipated to experience growth due to the increasing number of infertility cases. Infertility, diagnosed after a year of unsuccessful attempts to conceive, impacts a significant portion of the global adult population, affecting approximately 1 in 6 adults or 17.5% globally, as stated by the World Health Organization in April 2023. As a result, the rising prevalence of infertility cases is propelling the demand for assisted reproductive technology (ART), which encompasses fertility treatments involving both male and female reproductive components.

The escalating prevalence of obesity is poised to drive the growth of the ART market in the future. Obesity, characterized by excessive body fat accumulation that may affect health, can lead to irregular menstrual cycles, ovulatory dysfunction, and decreased sperm quality, thereby increasing infertility risks. The World Heart Federation reported in March 2023 that around 2.3 billion individuals, including adults and children, were affected by obesity or being overweight globally. Projections indicate that by 2025, this number may soar to 2.7 billion, underscoring the significant impact of obesity on fertility and the subsequent demand for specialized ART services.

A prominent trend shaping the ART market is the advancement of technology. Leading companies are actively developing technological solutions to fortify their positions within the industry. Notably, Alife Health introduced the Alife Assist platform in October 2022, an innovative suite of products leveraging data-driven insights and artificial intelligence (AI) to transform the in-vitro fertilization (IVF) process. This platform, consisting of Stim Assist, Embryo Assist, and Insights, caters to reproductive endocrinologists, embryologists, and clinic administrators, aiding in clinical decision-making, streamlining IVF clinic operations, and optimizing medication dosing, embryo grading, and real-time performance monitoring. The implementation of such technology not only enhances the patient experience but also improves success rates in IVF procedures.

Leading companies in the assisted reproductive technology (ART) sector are spearheading the development of innovative products to gain a competitive edge in the market. For example, in July 2023, Thermo Fisher Scientific Inc., a renowned US-based biotechnology firm, introduced two pioneering next-generation sequencing-based options specifically crafted to support preimplantation genetic testing-aneuploidy (PGT-A) in the context of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research. The cutting-edge products, namely the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, are tailored for use in reproductive health labs. These are the first research-use assays in the field, and they are compatible with the Ion Torrent Genexus Integrated Sequencer, providing a comprehensive workflow from the initial sample to the final result for aneuploidy analysis. PGT-A testing facilitates the identification of chromosomal irregularities in embryo samples, offering researchers invaluable genetic insights to potentially bolster the success rate of future pregnancies and improve the health of future generations. The Genexus Integrated Sequencer streamlines the research process by enabling templating, sequencing, and analysis on a single platform. Additionally, the Ion AmpliSeq Polyploidy Panel kit includes quality control features designed to detect contamination, prevent sample mix-ups, and identify triploidy in embryos.

In August 2021, Virtus Health Limited, an Australia-based company specializing in ART, executed the acquisition of Adora Fertility and three-day hospitals from Healius Limited for an estimated $45.0 million. This strategic acquisition is anticipated to fortify Virtus Health's portfolio, particularly in in-vitro fertilization (IVF). Adora Fertility, an Australia-based enterprise, provides ART services, including IVF and ICSI, catering to assisted reproductive technologies.

Major companies operating in the assisted reproductive technology market include Cooper Surgical Inc., Ferring Pharmaceuticals Ltd., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife AB, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific Inc., Boston Scientific Corporation, Anecova Sa, Carolinas Fertility Institute, Microm Ltd., Inception Sciences Inc., Progyny Inc., Oxford Gene Technology IP Ltd., IVI-RMA Global, Boston IVF, CARE Fertility Group, Virtus Health, Reproductive Medicine Associates of New York, Shady Grove Fertility, CCRM Fertility, New Hope Fertility Center, Houston Fertility Institute, Pacific Fertility Center, RMA of New Jersey, Sher Fertility Institute, IVF Florida, ORM Fertility, HRC Fertility, Arizona Center for Reproductive Endocrinology & Infertility, San Diego Fertility Center, Fertility Centers of Illinois

Europe was the largest region in the assisted reproductive technology market in 2023. North America was the second-largest region in assisted reproductive technology market. The regions covered in the assisted reproductive technology (ART) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the assisted reproductive technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The assisted reproductive technology market includes revenues earned by entities by gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.